Streptozocin is used to induce Type 1 diabetes for medical research. It has been used for the treatment of malignant insulinoma It is used mainly in the treatment of pancreatic (islet-cell) tumors.
Unless specified otherwise, MP Biomedical's products are for research or further manufacturing use only, not for direct human use. For more information, please contact our customer service department.
Treatment of pancreatic (islet-cell) tumors
|Alternate Names||N-(Methylnitrosocarbamoyl)-α-D-glucosamine; Streptozocin; STZ; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose|
|Application Notes||Streptozocin is used to induce Type 1 diabetes for medical research. It has been used for the treatment of malignant insulinoma It is used mainly in the treatment of pancreatic (islet-cell) tumors.|
|Base Catalog Number||100557|
|Beilstein Registry Number||2060675|
|Biochemical Physiological Actions||An N-nitroso-containing compound that acts as a nitric oxide donor in pancreatic islets; induces death of insulin-secreting cells, producing an animal model of diabetes. Potent DNA methylating agent that induces chromosomal breakage. Cytotoxic to neuroendocrine tumor cell lines that express the GLUT2 glucose transporter.|
|Extinction Coefficient||EmM(228 nm): 6.36 (ethanol)|
|Half Life||biological half-life in cell culture medium was shown to be approximately 19 minutes.|
|Melting Point||239Â° F (Decomposes) (NTP, 1992)|
|Molecular Weight||265.222 g/mol|
|Personal Protective Equipment||Eyeshields, full-face particle respirator type N100, Gloves, respirator cartridge, respirator filter|
|Purity||~75% α-anomer basis; ≥97%|
|Solubility||Soluble (NTP, 1992)|
|Typical Working Concentration||Has been used in intravenous injections in rats at a dose of 65 mg/kg body weight to induce diabetes (using cold 0.1 M citrate buffer pH 4.5). In rats and dogs, diabetes was induced using intravenous dosage of 50 mg/kg body weight (using 1-2% w/v solutions in saline buffered with citrate dextrose solution at pH 5.0).|